NOVOLIN GE 30/70 SUSPENSION

Kraj: Kanada

Język: angielski

Źródło: Health Canada

Składnik aktywny:

INSULIN INJECTION HUMAN BIOSYNTHETIC; INSULIN ISOPHANE HUMAN BIOSYNTHETIC

Dostępny od:

NOVO NORDISK CANADA INC

Kod ATC:

A10AD01

INN (International Nazwa):

INSULIN (HUMAN)

Dawkowanie:

30UNIT; 70UNIT

Forma farmaceutyczna:

SUSPENSION

Skład:

INSULIN INJECTION HUMAN BIOSYNTHETIC 30UNIT; INSULIN ISOPHANE HUMAN BIOSYNTHETIC 70UNIT

Droga podania:

SUBCUTANEOUS

Sztuk w opakowaniu:

10ML

Typ recepty:

Schedule D

Dziedzina terapeutyczna:

INSULINS

Podsumowanie produktu:

Active ingredient group (AIG) number: 0223312003; AHFS:

Status autoryzacji:

APPROVED

Data autoryzacji:

2011-01-07

Charakterystyka produktu

_ _
_Novolin_
_®_
_ge_
_ – _
_Product Monograph _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 1 of 52 _
_ _
PRODUCT MONOGRAPH
Schedule D
NOVOLIN
®
GE
Insulin, Human Biosynthetic
Injectable Solution/Suspension
Manufacturer’s Standard
Antidiabetic Agent
Novo Nordisk Canada Inc.
101-2476 Argentia Road
Mississauga, Ontario
L5N 6M1
DATE OF INITIAL APPROVAL:
January 7, 2011
CONTROL NO.: 227125
DATE OF REVISION: July 26, 2019
_ _
_Novolin_
_®_
_ge_
_ – _
_Product Monograph _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 2 of 52 _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................ 3
SUMMARY PRODUCT
INFORMATION.................................................................................
3
DESCRIPTION
............................................................................................................................
3
INDICATIONS AND CLINICAL USE
......................................................................................
3
CONTRAINDICATIONS
............................................................................................................
4
WARNINGS AND PRECAUTIONS
..........................................................................................
5
ADVERSE REACTIONS
............................................................................................................
8
DRUG INTERACTIONS
..........................................................................................................
10
DOSAGE AND ADMINISTRATION
......................................................................................
11
OVERDOSAGE
.........................................................................................................................
14
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................
15
STORAGE AND STABILITY
..................................................................................................
16
SPECIAL HANDLING INSTRUCTIONS
...........................